Retatrutide

Retatrutide is a novel triple agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. This multi-receptor approach makes it a highly sought-after research compound. Supplied at 30mg per vial, this research-grade peptide undergoes high purity synthesis with rigorous third-party HPLC and mass spectrometry testing to ensure consistent quality for advanced research applications. Each vial is lyophilized for maximum stability and shipped with proper cold-chain handling.